Efficacy of Double-Dose Hepatitis B Rescue Vaccination in HIV-Infected Patients
Authors:
- 1 July 2010
- journal article
- research article
- Published by SAGE Publications in AIDS Patient Care and STDs
- Vol. 24 (7) , 403-407
Abstract
Impaired hepatitis B virus vaccine (HBVV) efficacy has been observed in HIV-infected patients. We assessed the immunogenicity of double-dose (DD) hepatitis B virus revaccination in patients who had failed to respond to standard vaccination. A retrospective chart review of 4,663 patients ensued in two urban HIV clinics between January 2004 and March 2009. Of 363 patients who received three standard doses (SDs) of HBVV, 126 (34.7%) responded with detectable hepatitis B surface antibody [(HBsAb) HBsAb titer of ≥10 mIU/ml] and 237 (65.3%) nonresponders (NRs) remained seronegative. Among NRs, 61 received three to eight additional SDs of HBVV; 29 received three double doses (DDs) of HBVV (40 μg/dose), spaced at monthly dosing intervals; and 11 received from one to five additional SD HBVV (who remained seronegative) and then received three DDs HBVV. Response rate was significantly higher among the 40 DD recipients than among the 61 who received only additional SD (34/40, 85%, vs. 36/61, 59%; p = 0.006). In the revaccinated NR group (61 SD + 40 DD), a logistic regression analysis found that use of highly active antiretroviral therapy (HAART) (OR, 10.166; CI, 1.359–76.026; p = 0.024), and CD4 cell counts ≥200 cells/mm3 at the time of revaccination (OR, 9.233; CI, 1.393–61.207; p = 0.021) were associated with HBsAb response, as was DD HBV revaccination (OR, 4.177; CI, 1.282–13.614; p = 0.018). Rescue DD hepatitis B vaccination appears to improve the HBsAb response rate significantly in HIV-infected NR patients, especially after an adequate immune restoration with HAART. More prospective studies are needed to confirm these findings.Keywords
This publication has 16 references indexed in Scilit:
- A Prospective Open Study of the Efficacy of High‐Dose Recombinant Hepatitis B Rechallenge Vaccination in HIV‐Infected PatientsThe Journal of Infectious Diseases, 2008
- Immunological response to hepatitis B vaccination in patients with AIDS and virological response to highly active antiretroviral therapyScandinavian Journal of Infectious Diseases, 2008
- Co-infection of hepatitis B and hepatitis C virus in human immunodeficiency virus-infected patients in New York City, United StatesWorld Journal of Gastroenterology, 2008
- Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: A U.S.–Canadian multicenter studyJournal of Hepatology, 2007
- Prevention of viral hepatitis in HIV co-infectionJournal of Hepatology, 2006
- Natural history of chronic hepatitis B in co-infected patientsJournal of Hepatology, 2006
- Epidemiology of viral hepatitis and HIV co-infectionJournal of Hepatology, 2006
- Undetectable Plasma HIV RNA Load Predicts Success after Hepatitis B Vaccination in HIV-Infected PersonsClinical Infectious Diseases, 2005
- Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohortAIDS, 2005
- Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double doseVaccine, 2005